Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-SUUP
2025-524679-22-00Phase 2Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Mar 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glimepiride in maturity-onset diabetes of the young type 3 and maturity-onset diabetes of the young type 1 (MODY1), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Mean difference in time in tight range (3.9–7.8 mmol/l). Planned start Mar 2026; status: authorised.
02
Drugs
glimepiride
03
Conditions
maturity-onset diabetes of the young type 3maturity-onset diabetes of the young type 1 (MODY1)
Beyond the preview
Go deeper on 2025-524679-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524679-22-00.